NICE issues positive recommendation for Astellas' Xtandi
In an about turn, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today issued a Final Appraisal Determination (FAD) recommending Japanese drug major Astellas Pharma’s (TYO: 4503) Xtandi (enzalutamide) as an option for the treatment of metastatic hormone-relapsed prostate cancer in adults whose disease has progressed during or after docetaxel containing chemotherapy.
This announcement follows issuance of a first Appraisal Consultation Document (ACD) in October 2013ii and a second one in January 2014.The latter ACD included a restriction on the use of enzalutamide post-abiraterone,which, following consultation, has been removed, noted Astellas.
Decision based on new observations
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze